期刊文献+

丹参素对巨噬细胞肝X受体的活化及胆固醇外流的影响 被引量:2

The impacts of Danshensu on the activation of liver X receptor and the cholesterol efflux of macrophage
原文传递
导出
摘要 目的:研究丹参素对巨噬细胞的肝X受体(LXR)及其下游的目的基因的表达和胆固醇外流的影响,探讨丹参素对LXR信号系统的作用。方法:分离人外周血的单核细胞,并转化为巨噬细胞。在丹参素的作用下,观察巨噬细胞的aopA-I介导的胆固醇外流的变化和LXR及其下游目的基因的mRNA及蛋白的表达。结果:丹参素增强细胞内胆固醇的外流,使胆固醇外流的基因LXRα及其下游的一些目的基因表达上调,并呈剂量依赖性。结论:巨噬细胞在丹参素的作用下,上调LXR及其下游影响胆固醇代谢的目的基因,从而使胆固醇外流增强。 Objective:To study the effect of Danshensu on the expression of liver X receptor alfa (LXR) and its target genes and the cholesterol efflux of human macrophages. Method: Human peripheral blood monocytes were separated and translated into macrophages. Macrophages were stimulated with or without Danshensu. Cholesterol efflux mediated by ApoA-I-was detected by liquid scintillation counting method. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of LXRa and its target genes, While the pro- tein expression were determined by Western blotting. Result: Incubation with Danshensu, the cholesterol efflux was increased, and both the mRNA and protein expression of LXRa and its target genes were up-regulated by a dose dependently (5--10/mol · L-1) manner in human monocyte-derived macrophage mediated by apolipoprotein AI. Conclusion:The expression of LXR and its target genes influenced cholesterol metabolism were increased by stimulated with Danshensu in macrophages, resulted in the cholesterol efflux increased.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第10期778-780,共3页 Journal of Clinical Cardiology
基金 国家自然科学基金地区基金项目(No:81160489)
关键词 丹参素 胆固醇外流 巨噬细胞 肝X受体 Danshensut cholesterol efflux macrophage liver X receptor
  • 相关文献

参考文献10

  • 1WANG L, BAO Y, YANG Y, et al. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay[J]. J Biomol Screen,2010,15:239-250.
  • 2SUZUKI S, TOMOKO N M, TAMEHIRO N, et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via liver X receptor-independent mechanism[J]. Arterioscler Thromb Vasc Biol, 2004,24 : 519 - 525.
  • 3LING R, BORNFELDT K E. Cyclic AMP-specific phos- phodiesterase 4 inhibitors promote ARCA1 expression and cholesterol efflux[J]. Biochemical and Biophysical Research Communications, 2002,290: 663- 669.
  • 4SUZUKI S, TOMOKO N M, TAMEHIRO N, et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via liver X receptor-independent mechanism[J]. Arterioscler Thromb Vasc Biol, 2004,24 : 519- 525.
  • 5冯忠军,金玉怀,戴华.抗氧化低密度脂蛋白抗体与冠心病的关系[J].临床心血管病杂志,2003,19(10):588-590. 被引量:7
  • 6钱宗杰,曾秋棠.冠心病患者巨噬细胞肝X受体的活化与胆固醇外流[J].中国病理生理杂志,2006,22(11):2146-2150. 被引量:2
  • 7VON ECKARDSTEIN A, NOFER J R, ASSMANN G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport[J]. Arterioscler Thromh Vasc Biol, 2001, 21:13-27.
  • 8钱一欣,倪兆慧.肝X受体在代谢和炎症中的作用[J].临床心血管病杂志,2007,23(11):806-810. 被引量:3
  • 9LIBBY P, OKAMOTO Y, ROCHA V Z, et al. Inflammation in atherosclerosis: Transition from theory to practice[J]. Circ J, 2010,74 : 213 - 220.
  • 10LEVIN N, BISCHOFF E D, DAIGE C L, et al. Macrophage liver X receptor is required for antiatherogenic activi- ty of LXR agonists[J]. Arterioscler Thromb Vasc Biol, 2005,25:135- 142.

二级参考文献53

  • 1Lopes-Virella M F, Virella G. Cytokines, modified lipoproteins and arteriosclerosis in diabetes. Diabetes, 1996,45(Suppl 3) :S40-S44.
  • 2Steinberg D, Parthasarathy S, Carew T E, et al. Beyond cholesterol: Modifications of low-density lipoprorein that increase its atherogenicity. N Eng J Med,1989,320: 915-923.
  • 3BouUier A, Hamon M, Walters-Laporte E, et al. Detection of autoantibodies against oxidized low density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta, 1995,238:1-10.
  • 4Witztum J L, Palinski W. Are immunological mechanisms relevant for the development of atherosclerosis? Clin Immunoh 1999,90 : 153 - 156.
  • 5Parums D V, Brown D L, Mitchinsin M J. Serum antibodies to oxidized low-density lipoprotein and ceroid in chonic periaortitis. Arch Pathol Lab Med, 1990, 114: 383-387.
  • 6Bui M N, Sack M N, Moutsatsos G, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J, 1996, 131 :663-667.
  • 7Cornacoff J B, Hebert L A, Smead W L, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest, 1983,71 :236-247.
  • 8Lougheed M, Zhang H F, Steinbrecher U P. Oxidizedlow density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Bio Chem, 1991,266: 14519-14525.
  • 9Witztum J L, Steinberg D. Roie of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 1991,88:1785-1792.
  • 10Lusis AJ.Atherosclerosis[J].Nature,2000,407(6801):233-241.

共引文献9

同被引文献48

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部